Previous issue | Volume 89 | ESPE2018 | Next issue

57th Annual ESPE

Athens, Greece
27 Sep 2018 - 29 Sep 2018

Card image cap
ESPE 2018 57th European Society for Paediatric Endocrinology Annual Meeting 27-29 September 2018 Athens, Greece

Free Communications

Late Breaking

Burosumab Improved Rickets, Phosphate Metabolism, and Clinical Outcomes Compared to Conventional Therapy in Children with X-Linked Hypophosphatemia (XLH) - A Randomized Controlled Phase 3 Study
aKarolinska Institutet, Stockholm, Sweden; bÖrebro University, Örebro, Sweden; cShriners Hospitals for Children, St Louis, Missouri, USA; dIndiana University School of Medicine, Indianapolis, Indiana, USA; eThe Children’s Hospital at Westmead, Sydney, Australia; fUniversity of California, San Francisco, California, USA; gUniversity of Ottawa, Ottawa, Ontario, Canada; hVanderbilt University School of Medicine, Nashville, Tennessee, USA; iRoyal Manchester Children’s Hospital, Manchester, UK; jOsaka Hospital, Japan Community, Healthcare Organization, Osaka, Japan; kOsaka University Graduate School of Medicine, Osaka, Japan; lSeoul National University Children’s Hospital, Seoul, Democratic People’s Republic of Korea; mUltragenyx Pharmaceutical Inc., Novato, California, USA; nShriners Hospital for Children-Canada, McGill University, Montreal, Canada
hrp0089fc10.1
Efficacy and Safety of Once-Weekly Somapacitan in Childhood Growth Hormone Deficiency: Results of a Randomised Open-Label, Controlled Phase 2 Trial
aKarolinska Institutet and Pediatric Endocrinology Unit, Karolinska University Hospital, Stockholm, Sweden; bNovo Nordisk, Søborg, Denmark; cNational Center for Child Health and Development, Tokyo, Japan; dHirabai Cowasji Jehangir Medical Research Institute, Jehangir Hospital, Pune, India; eFaculty of Medicine, UMC-University Children’s Hospital, University of Ljubljana, Ljubljana, Slovenia; fWinthrop University Hospital, Mineola, New York, USA
hrp0089fc10.2
Identification of the MAPK/ERK Pathway as a Novel Therapeutic Target in Adamantinomatous Craniopharyngioma
aDevelopmental Biology and Cancer Programme, Birth Defects Research Centre, UCL Institute of Child Health, London, UK; bHistopathology Department, Great Ormond Street Hospital NHS Trust, London, UK; cInfection, Immunity and Inflammation Programme, UCL Great Ormond Street Institute of Child Health, University College London, London, UK; dHaematology and Oncology Department, Great Ormond Street Hospital NHS Trust, London, UK; eRheumatology Department, Great Ormond Street Hospital NHS Trust, London, UK
hrp0089fc10.3
Hypothalamus Sparing Surgery Improves the Outcome of Patients with Severe Initial Hypothalamic Involvement of Childhood Craniopharyngioma: Results of the Prospective Multinational Trial KRANIOPHARYNGEOM 2007
aDepartment of Pediatrics and Pediatric Hematology/Oncology, Klinikum Oldenburg AöR, Medical Campus University Oldenburg, Oldenburg, Germany; bDepartment of Endocrinology and Diabetology, The Children’s Memorial Health Institute, Warsaw, Poland; cDepartment of Neuroradiology, University Hospital, Würzburg, Germany; dDepartment of Pediatric Oncology and Hematology, University Hospital, Bonn, Germany; eInstitute of Biostatistics and Clinical Research, University of Münster, Munster, Germany
hrp0089fc10.4
A 5-Year Single-Centre Experience on the Safety and Efficacy of Sirolimus Therapy used for the Treatment of Congenital Hyperinsulinaemic Hypoglycaemia
aEndocrinology Department, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK; bSection of Genetics and Epigenetics in Health and Disease, Genetics and Genomic Medicine Programme, University College London Great Ormond Street Hospital Institute of Child Health, London, UK; cHistopathology Department, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK; dMolecular Genetics Department, University of Exeter Medical School, Exeter, UK
hrp0089fc10.5
Primary Ovarian Insufficiency Incidence Rate and ETIOLOGY AMONG ISRAELI ADOLESCENTS between the Years 2000-2016 - A Multi-Center Study
aPediatric Endocrine and Diabetes Unit, Edmond and Lily Safra Children’s Hospital, Sheba Medical Center, Ramat Gan, Israel; bSackler School of Medicine, Tel-Aviv University, Tel Aviv, Israel; cThe Jesse Z and Sara Lea Shafer Institute for Endocrinology and Diabetes, National Center for Childhood Diabetes, Schneider Children’s Medical Center of Israel, Petach Tikva, Israel; dPediatric Endocrinology Unit, Kaplan Medical Center, Rehovot, Israel; eThe School of Medicine in the Hebrew University, Jerusalem, Israel; fPediatric Endocrinology and Diabetes Unit, Dana-Dwek Children Hospital, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; gPediatric Endocrinology Unit, Division of Pediatrics, Assaf Harofeh Medical Center, Zerifin, Israel; hPediatric Endocrinology Clinic, Armon Child Center, Clalit Health Services, Haifa, Israel; iPediatric Endocrine Unit, Ha’Emek Medical Center, Affula, Israel; jThe Rappaport Faculty of Medicine, Technion, Haifa, Israel; kPediatric Endocrinology and Metabolic Unit, Soroka University Medical Center and the Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel; lPediatric Endocrine and Diabetes Unit, E. Wolfson Medical Center, Holon, Israel; mPaediatric Endocrine Unit, Rambam Health Care Campus, Haifa, Israel; nMeir Medical Center, Kfar Saba, Israel; oDivision of Pediatric Endocrinology, Hadassah Hebrew University Medical Center, Jerusalem, Israel; pPediatric Department, Bnei Zion Medical Center, Haifa, Israel; qMigdale Ha’Meha, Clalit Health Services, Central District, Tel Aviv, Israel; rDivision of Pediatric Endocrinology, Shaare Zedek Medical Center, Jerusalem, Israel; sMaccabi Health Services, Central District, Rishon Lezion, Israel; tZabludowicz center for Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer, Ramat Gan, Israel
hrp0089fc10.6